Navigation Links
PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting
Date:11/4/2010

PRINCETON, N.J., Nov. 4, 2010 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that more than twenty posters will be presented by Company scientists at the 2010 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition being held from November 14 -18 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Leading PharmaNet's delegation at AAPS will be Riaz Bandali, President, Early Stage Development, who is responsible for the Company's Phase I clinics and bioanalytical laboratories. Mr. Bandali and other PharmaNet experts will be at booth 1519 to discuss the Company's industry-leading bioanalytical capacity, the Company's offerings of more than 1000 validated methods and its custom method development and validation, bioanalytical mass spectrometry, and immunochemistry services.

Attendees are invited to attend the PharmaNet poster presentations:  

Monday, November 15, 2010, 13:00 – 17:00 Exhibit Hall B1Quantitative Determination of Alendronate Sodium in Human Plasma Using a Validated LCMSMS Method: Application to Clinical Pharmacokinetic Studies, (M1500)

Tuesday, November 16, 2010, 8:00 – 12:00 Exhibit Hall B1Leuprolide: A Sensitive LCMSMS Method for the Analysis of a Large Molecule, (T2245)

Development and Validation of a Dried Blood Spot Assay for the Determination of Midazolam in Human Whole Blood by LCMSMS, (T2253)

Importance of Incurred Samples Reanalysis to Assess the Reproducibility of Exemestane Assay, (T2288)

Specific, Selective and Robust Determination of Quaternary Ammonium Compound Scopolamine N-Butyl in Human Plasma by LCMSMS, (T2252)

Innovative Determination of Unbound Docetaxel in Human Plasma using a Filtration Device, (T2271)

A Robust and Specific Analytical Method for the Determination of Dienogest, a Hormone Replacement Therapy, (T2300)

Derivatization of Phenolic Co-Extracts for Better Sensitivity and Selectivity of Etonogestrel Assay at Low Picograms Levels, (T2282)

Robust Pharmacokinetic Characterization of Methylprednisolone in Normal Healthy Volunteers using a Highly Sensitive Analytical Method, (T2314)

A validated LC-MS/MS Method for the Simultaneous Determination of the Anti-Cancer Agent Capecitabine and its Metabolite, 5'-Deoxy-5-fluorocytidine (5'-DFCR) in Human Plasma, (2287)

Brivanib Alaninate Can Be Safely Co-Administered with CYP2C8 Substrates in Humans, (T2380)

Development of a Single Method for the Determination of Buprenorphine, Norbuprenorphine, and their Glucuronide Metabolites in Human Plasma Using LC/MS/MS, (T2258)

High Resolution Accurate Mass LC-MS for In Vivo Fast PK Studies, (T2319)

On-the-Fly Metabolite ID & Quantitation During Fast PK Bioanalysis Using High Resolution Mass Spectrometry, (T2285)

A Multi-Point Staggered Injection Technique for LCMSMS Bioanalysis: Accounting for Standard Curve Divergence During Sample Analysis, (T2325)

Comparative Analysis of Buprenorphine and Oxycodone in Human Dried Blood Using LCMSMS, (T2341) Optimizing Tissue Analysis for LC-MS/MS in Support of Drug Distribution Studies, (T2332)

Integration of Hamilton Robotics into a LIMS Platform in Support of Regulated and Discovery Bioanalysis, (T2333)

Development of Liquid Handler Pipetting Settings for Sample Additions in Biological Matrices to Assay Plates for Quantitation Assays and Anti-Drug Antibody Assays, (T2438)

Tuesday, November 16, 2010, 13:00 – 17:00 Exhibit Hall B1Development and Optimization of an Immunoassay for Quantifying Glucagon in Cyano Monkey Serum, (T3277)

Wednesday, November 17, 2010, 13:00 – 17:00 Exhibit Hall B1High-Throughput Drug-Protein Binding Assay in Whole Blood, Plasma, and Brain Tissue, (W5309)

Thursday, November 18, 2010, 8:00 – 12:00 Exhibit Hall B1Method Development of an Assay for the Quantitation of an Adsorption-Prone Compound in Human Urine, (R6348)

A Rapid Simple Validated LCMSMS Method for Analysis of Bilastine in Human Plasma and Urine, (R6359) 

Use of Hemolysed Plasma for Matrix Effect Evaluation in the Validation of a LCMSMS Method, (R6368)

For more information about PharmaNet's comprehensive range of services, please visit us at booth 1519. Alternatively, please email earlystage@pharmanet.com or visit www.pharmanet.com.

About PharmaNet Development Group, Inc.PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.Contact: Anne-Marie HessPhone:   (609) 951-6842E-mail:   ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaNet Development Group Agrees to be Acquired by JLL Partners
2. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
3. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
4. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
5. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
6. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
7. Christopher Brennan Joins PharmaNet Development Group as General Counsel
8. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
9. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
10. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
11. PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the formation of the Steering ... --> --> Pelvic masses can ... diagnosis and management. Once pregnancy is ruled out, pelvic ... and ovaries, advanced endometriosis, benign ovarian tumors and gastrointestinal ...
(Date:2/11/2016)... 11, 2016  Bioethics International, a not-for-profit organization focused on ... marketed and made accessible to patients around the world, today ... named the publication of the Good Pharma Scorecard ... also featured as one of BMJ Open ,s ,Most ... that are most frequently read. Ed Sucksmith , ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today announced ... Portland, Oregon -based community care organization ... population health analytics, quality reporting and care management ... strengthen its team of quality managers, analysts and ... the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
Breaking Biology News(10 mins):